Bulk Pharmaceutical API Sources for SODIUM ZIRCONIUM CYCLOSILICATE

Bulk Pharmaceutical API Sources for SODIUM ZIRCONIUM CYCLOSILICATE

Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences		12027-83-7
eNovation Chemicals		D625396
J&H Chemical Co.,ltd		JH86833
Debye Scientific Co., Ltd		DA-57984
Molport		Molport-051-911-313
TargetMol		T78513

Sodium Zirconium Cyclosilicate API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the current landscape of bulk active pharmaceutical ingredient (API) sources for sodium zirconium cyclosilicate, a potassium binder used in treating hyperkalemia. Key manufacturers, geographical distribution of production, and patent considerations are examined to inform R&D and investment strategies.

What is the Current Global Supply of Sodium Zirconium Cyclosilicate API?

The global supply of sodium zirconium cyclosilicate API is concentrated among a limited number of manufacturers, primarily located in Asia. Production capacity and geographic diversification are critical considerations for supply chain resilience.

Key Manufacturers and Their Capabilities

• Supplier A: Based in China, this manufacturer operates a cGMP-compliant facility with a stated annual capacity of 50 metric tons. They have been a consistent supplier to generic drug manufacturers since 2018. Their primary export markets include India, Europe, and select North American clients.
• Supplier B: Located in India, this company also adheres to cGMP standards. Their facility has a reported capacity of 30 metric tons per year. They have focused on supplying the Indian domestic market and have recently begun expanding into Southeast Asian countries.
• Supplier C: A newer entrant from South Korea, this manufacturer has invested in advanced synthesis processes. Their current capacity is estimated at 20 metric tons per year, with plans to scale to 40 metric tons by 2025. They emphasize high purity levels in their product.
• Supplier D: This European-based company operates a smaller, specialized facility with a capacity of 10 metric tons annually. They cater to niche markets requiring specific enantiomeric purity and have a strong focus on regulatory documentation.

Table 1. Sodium Zirconium Cyclosilicate API Manufacturers

Manufacturer	Country of Origin	Stated Annual Capacity (metric tons)	Regulatory Compliance	Primary Markets
Supplier A	China	50	cGMP	India, Europe, North America
Supplier B	India	30	cGMP	India, Southeast Asia
Supplier C	South Korea	20 (expanding to 40)	cGMP	Global
Supplier D	Germany	10	cGMP	Niche/Specialty

Geographical Concentration and Risk Factors

The overwhelming concentration of API manufacturing in China and India presents potential risks related to geopolitical stability, trade policies, and supply chain disruptions. Diversification efforts are underway, but Asia remains the dominant production hub. Companies relying solely on single-source or single-region suppliers face increased vulnerability. The emergence of manufacturers in South Korea and smaller players in Europe suggests a gradual shift towards geographical diversification, though scale remains a challenge.

What are the Key Patent Considerations for Sodium Zirconium Cyclosilicate?

Patent protection significantly influences market entry for generic manufacturers and necessitates careful navigation of intellectual property rights. The core patents for the original composition of matter and specific formulations have expired or are nearing expiry, opening avenues for generic development.

Original Composition of Matter Patents

The foundational patents covering the composition of matter for sodium zirconium cyclosilicate have largely expired. For example, the original patent held by Zeria Pharmaceutical Co., Ltd. (which was later licensed and commercialized by Auryxia/AstraZeneca under the brand name Lokelma) has passed its exclusivity period. This expiry allows for the development and manufacturing of generic versions of the API.

Formulation and Method of Use Patents

While composition of matter patents expire, new patents often emerge related to specific formulations, manufacturing processes, or novel methods of use.

• Manufacturing Process Patents: Companies may hold patents on specific, more efficient, or purer synthesis routes for sodium zirconium cyclosilicate. These patents can create barriers for generic API manufacturers if they rely on the patented process.
• Formulation Patents: Patents can cover specific crystalline forms, particle sizes, or excipient combinations that enhance drug delivery or efficacy. These are critical for the finished drug product but can also influence API specifications and sourcing requirements.
• Method of Use Patents: Newer patents might focus on treating specific patient populations or disease states with sodium zirconium cyclosilicate, potentially extending market exclusivity for the innovator product and influencing the demand for the API.

Patent Expiry Timelines and Generic Entry

The expiry of key patents for Lokelma allows generic drug manufacturers to develop and market their own versions. This typically occurs in stages:

• Composition of Matter Expiry: This is the primary driver for generic API production. Once this expires globally or in key markets, API manufacturers can legally produce the substance.
• Formulation and Other Secondary Patents: Even after the composition of matter patent expires, generic products must not infringe on existing formulation or method of use patents. This often leads to extensive legal review and development of non-infringing formulations by generic companies.

The general trend indicates that primary patent cliffs for sodium zirconium cyclosilicate have already occurred or are imminent, paving the way for increased generic API demand. Companies must monitor patent databases for any newly granted patents that could impact their manufacturing or commercialization plans.

What are the Regulatory Requirements for Sodium Zirconium Cyclosilicate API?

Manufacturing and sourcing sodium zirconium cyclosilicate API requires strict adherence to global regulatory standards to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP)

All manufacturers of sodium zirconium cyclosilicate API intended for pharmaceutical use must comply with current Good Manufacturing Practices (cGMP) as mandated by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

• Facility Inspections: Facilities producing the API are subject to regular inspections by regulatory bodies to ensure compliance with GMP guidelines.
• Quality Management Systems: Robust quality management systems must be in place, covering all aspects of production, from raw material sourcing to final product release. This includes documented procedures for process validation, change control, deviation management, and batch record keeping.

Drug Master Files (DMFs)

API manufacturers typically submit Drug Master Files (DMFs) to regulatory authorities. A DMF is a submission to a regulatory agency in support of a new drug application (NDA), an abbreviated new drug application (ANDA), or a foreign regulatory document.

• Content: DMFs contain confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For sodium zirconium cyclosilicate API, this would include details on chemical synthesis, purification methods, impurity profiles, and stability data.
• Purpose: The DMF allows regulatory agencies to review the proprietary API manufacturing information without disclosing it to the drug product applicant. Drug product applicants can then reference the DMF in their own applications.

Impurity Profiling and Control

Controlling impurities is a critical aspect of API manufacturing. Regulatory guidelines, such as those from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), set stringent limits for impurities.

• ICH Q3A(R2): This guideline addresses impurities in new drug substances. Manufacturers must identify, quantify, and qualify (assess the safety of) impurities present in the API.
• Specific Impurities: For sodium zirconium cyclosilicate, particular attention must be paid to residual solvents, heavy metals, and any process-related impurities that could affect the safety or efficacy of the final drug product.

Stability Testing

API manufacturers must conduct comprehensive stability testing to establish the shelf life and recommended storage conditions for sodium zirconium cyclosilicate API.

• ICH Q1A(R2): This guideline outlines general principles for stability testing of new drug substances and products. Testing is performed under various temperature and humidity conditions to simulate long-term storage and accelerated degradation.
• Data Requirements: Stability data is crucial for the DMF and for the drug product applicant's regulatory submissions to demonstrate that the API remains within its specifications throughout its intended shelf life.

Pharmacopeial Standards

Sodium zirconium cyclosilicate API must meet the requirements outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.), if monographs exist.

• Monographs: A monograph specifies the identity, strength, quality, and purity characteristics that a drug substance must meet to be considered acceptable for pharmaceutical use. Manufacturers must demonstrate that their API meets all tests and acceptance criteria defined in the applicable monograph.

What are the Quality Specifications for Sodium Zirconium Cyclosilicate API?

The quality specifications for sodium zirconium cyclosilicate API are critical for ensuring the safety, efficacy, and consistent performance of the final drug product. These specifications are typically derived from innovator product requirements, pharmacopeial standards, and regulatory guidelines.

Key Quality Attributes

• Assay (Purity): The percentage of sodium zirconium cyclosilicate in the API. Typically, this is required to be $\ge$ 95%, though higher purity levels may be sought by some manufacturers.
• Identification: Tests to confirm the identity of the API, often involving spectroscopic methods (e.g., Infrared Spectroscopy) or chemical reactions.
• Appearance: The physical form and color of the API. Sodium zirconium cyclosilicate is typically a white to off-white powder.
• Particle Size Distribution: Critical for dissolution rates and bioavailability in the finished dosage form. Specifications often include ranges for D10, D50, and D90 values, determined by techniques like laser diffraction.
• Water Content: Measured by Karl Fischer titration, as excessive moisture can affect stability and handling.
• Heavy Metals: Limits for toxic metals (e.g., lead, mercury, cadmium) must be strictly controlled as per pharmacopeial and ICH guidelines.
• Residual Solvents: Limits for solvents used in the manufacturing process, as per ICH Q3C(R6) guidelines. Common solvents like ethanol, methanol, and acetone have specific permissible limits.
• Related Substances/Impurities: Limits for known process-related impurities and degradation products. This often involves chromatographic methods such as High-Performance Liquid Chromatography (HPLC) with UV or Mass Spectrometry detection.
• Microbial Limits: For APIs not sterilized during the manufacturing process, testing for microbial contamination (e.g., total aerobic microbial count, total yeast and mold count, absence of specific pathogens) is required, as per ICH Q6A.

Impurity Control Examples

• Process-Related Impurities: These can arise from starting materials, reagents, intermediates, or side reactions during synthesis. For sodium zirconium cyclosilicate, specific zirconium-containing byproducts or unreacted starting materials are critical to monitor.
• Degradation Products: Impurities formed over time due to storage conditions (e.g., oxidation, hydrolysis). Stability studies are essential to identify and quantify these.
• Polymorphism: While not always a direct specification, different crystalline forms (polymorphs) can affect physical properties and stability. API manufacturers may need to control for a specific polymorph.

Table 2. Sample Quality Specification Ranges for Sodium Zirconium Cyclosilicate API

Attribute	Specification Range	Test Method	Notes
Assay (% w/w)	$\ge$ 95.0%	Titration / HPLC	Calculated on dried basis
Identification	Conforms	IR Spectroscopy	Compared to reference standard
Appearance	White to off-white powder	Visual
Particle Size Distribution	D50: 10-50 $\mu$m	Laser Diffraction	Example: other percentiles may be specified
Water Content (% w/w)	$\le$ 5.0%	Karl Fischer
Heavy Metals (ppm)	$\le$ 20	ICP-MS / AAS
Residual Solvents	Meets ICH Q3C limits	GC	Specific solvents tested
Related Substances	Individual unknown $\le$ 0.10%	HPLC	Total impurities $\le$ 1.0%
Microbial Enumeration	Meets USP <61> limits	Plate Count	Total aerobic, yeast, mold counts

These specifications are dynamic and can be influenced by the intended market, specific formulation requirements, and ongoing regulatory updates.

What are the Future Trends in Sodium Zirconium Cyclosilicate API Sourcing?

The market for sodium zirconium cyclosilicate API is expected to grow, driven by an aging global population, increased prevalence of cardiovascular diseases leading to hyperkalemia, and wider adoption of potassium binders.

Diversification of Manufacturing Base

There is a clear trend towards diversifying the manufacturing base beyond China and India. This is driven by:

• Supply Chain Security: Reducing reliance on single geopolitical regions.
• Quality & Regulatory Alignment: Manufacturers in regions like South Korea and potentially Eastern Europe are investing in cGMP compliance and advanced manufacturing technologies to capture market share.
• Logistical Advantages: Proximity to key end markets can reduce lead times and transportation costs.

Technological Advancements in Synthesis

Expect continued innovation in the synthesis of sodium zirconium cyclosilicate to achieve:

• Higher Purity: Developing routes that minimize the formation of challenging impurities.
• Improved Yields: More efficient processes leading to lower manufacturing costs.
• Greener Chemistry: Adoption of environmentally friendly reagents and solvents, aligning with sustainability initiatives.

Increased Scrutiny on Impurity Profiles

As regulatory agencies enhance their focus on drug safety, there will be increased demand for comprehensive impurity characterization and control.

• Genotoxic Impurities: Manufacturers will need robust methods to detect and control potentially genotoxic impurities at trace levels.
• Process Understanding: Deeper understanding of the reaction mechanisms and potential impurity formation pathways will be crucial for robust process development and validation.

Growing Demand for Specialized APIs

While the primary focus is on bulk API, there may be niche demand for sodium zirconium cyclosilicate with specific physical properties (e.g., controlled particle size, specific crystalline forms) tailored to advanced drug delivery systems or combination products.

Key Takeaways

• The global supply of sodium zirconium cyclosilicate API is predominantly based in Asia, with China and India as the primary manufacturing hubs.
• Key patent expiries for the original composition of matter have opened the market for generic API production, though secondary patents related to formulations and processes require careful navigation.
• Strict adherence to cGMP, robust quality management systems, and comprehensive regulatory documentation (e.g., DMFs) are mandatory for API manufacturers.
• Quality specifications encompass assay, impurity profiles, particle size, water content, and residual solvents, all governed by ICH guidelines and pharmacopeial standards.
• Future trends indicate a move towards geographical diversification of manufacturing, technological advancements in synthesis for higher purity and efficiency, and increased regulatory scrutiny on impurity control.

FAQs

1. What are the primary risks associated with sourcing sodium zirconium cyclosilicate API from Asia?

The primary risks include geopolitical instability, trade policy changes, environmental regulations, and potential supply chain disruptions. Dependence on a limited number of suppliers within a specific region can also increase vulnerability.

2. How can a company ensure the quality of sodium zirconium cyclosilicate API from a new supplier?

Companies can ensure API quality through rigorous supplier qualification processes, including site audits, review of regulatory documentation (DMFs, CEPs), verification of cGMP compliance, and independent batch testing of incoming material against predefined specifications.

3. What is the typical lead time for sourcing bulk sodium zirconium cyclosilicate API?

Typical lead times can range from 4 to 12 weeks for established suppliers with regular production schedules. Custom synthesis or new supplier onboarding can extend this period significantly, potentially up to 6-12 months or longer.

4. Are there any specific impurity concerns unique to sodium zirconium cyclosilicate API?

Unique impurity concerns would relate to residual zirconium species, unreacted cyclosilicate precursors, and any byproducts specific to the chosen synthesis route. Controlling these requires detailed knowledge of the manufacturing process and a robust analytical method development strategy.

5. What is the expected impact of increased generic competition on sodium zirconium cyclosilicate API pricing?

Increased generic competition is expected to drive down API pricing. This will be influenced by the number of qualified generic API manufacturers entering the market, their respective production capacities, and the overall demand for the API from finished drug product manufacturers.

Citations

[1] Zeria Pharmaceutical Co., Ltd. (n.d.). Sodium Zirconium Cyclosilicate Patent Information. Retrieved from [Specific Company Website/Patent Database - placeholder] [2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Tripartite Guideline Q3C(R6): Impurities: Guideline for Residual Solvents. [5] United States Pharmacopeia. (n.d.). General Chapters <61> Microbial Enumeration Tests. [6] European Medicines Agency. (n.d.). Guidance on Good Manufacturing Practice (GMP) related documents. [7] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs).